FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2950280971> ?p ?o ?g. }

• W2950280971 endingPage "36" @default.
• W2950280971 startingPage "36" @default.
• W2950280971 abstract "radiotherapy; nanoparticles: radiotherapy; nanoparticlesMILAN—Injections of inert hafnium nanoparticles into tumors doubled pathologic complete response rates to subsequent radiotherapy for patients with soft tissue sarcomas (STS) of limbs in comparison with patients having similar radiotherapy without prior hafnium injections. These findings from the Act.In.Sarc multinational phase II/III study were reported at the 2019 European Society for Radiotherapy and Oncology (ESTRO) conference (Abstract OC-0271). “Hafnium oxide nanoparticles are first-in-class radio-enhancers,” said study co-author Juliette Thariat, MD, PhD, Professor of Radiation Oncology at the Centre François Baclesse in Caen, northern France. “We have proof of concept for a tumor type that was radio-resistant. We have very good tumor response without increased toxicity. This is very promising for many other tumor types.”Juliette Thariat, MD, PhD: Juliette Thariat, MD, PhDHafnium can enhance the effect of radiation because the large mass of each atom can absorb correspondingly large amounts of energy when irradiated. If such atoms are injected into tumor cells, they absorb far more energy from the radiotherapy than would be absorbed by the much lighter elements, which comprise most of the mass of the cancer cells. Thariat said this means that the nanoparticles can then release this energy more locally: precisely into the tumor, where it is needed to kill cancer cells. “We injected the tumors of the patients who had sarcomas of the limbs or the soft tissues [for whom] we would have been afraid they would not be able to receive complete surgery. After one single injection [of] nanoparticles (later activated by the radiation), we would expect the efficacy of the radiation would increase and would make the safety margins of the resection larger.” Study Details The phase II/III trial had a standard arm with patients who received preoperative radiation—50 Gray (GY) for 5 weeks—and then surgery a few weeks after. Those in the experimental arm had their radiation therapy preceded by an injection of hafnium oxide nanoparticles and then had the same surgical options. A total of 180 patients with locally advanced STS of the extremity or trunk wall were randomized (with all patient and tumor characteristics well-balanced, apart from sex) to receive a single intratumoral hafnium oxide injection and radiotherapy, or radiotherapy alone followed by surgical resection. Pathologic complete response rate was the main endpoint of the trial because it was regarded as a good surrogate for local control and for achieving clear resection margins, Thariat explained. “The first endpoint was met,” she noted. “We doubled the pathological response rate from 7.9 to 16.1 percent, which is quite good—especially in sarcomas which are radio-resistant tumors. And this translated into better safe resection margin rates. We are [now] expecting the longer-term results.” Seventy-seven percent of patients treated with hafnium had clear surgical margins as compared with 64 percent of those in the control arm. The limb amputation rate was decreased by 50 percent in the experimental arm. The injections showed “very good local tolerance” without the need for modifying radiotherapy. The intratumoral injections caused pain in 12 patients and grade 3-4 acute immune reactions in seven. But these adverse events were reported as “of short duration, manageable, and, in some cases, resolved spontaneously.” The investigators concluded that both the primary and secondary endpoints were met with a safety profile that was similar in both arms. The authors also noted that hafnium before radiotherapy represented a “new preoperative treatment option for locally advanced STS.” Change Practice? When asked if the study should change practice for soft tissue sarcoma, Thariat said it should. “Patients should probably receive the injection of nanoparticles before radiation.” And the reassurance the technique brings about margin safety was also on her list of pluses. “There should be a clinical benefit. We are still waiting for longer, more clinical endpoints to really answer that question. But the primary endpoint is already very good. There's a clear message that the trial was very positive,” she said. And she thought the findings could have strong implications well beyond sarcoma. “There are many other tumor settings where radio-enhancing nanoparticles would be interesting,” Thariat said. She considered head and neck cancer treatment, for example, could improve. “Head and neck tumors are not that radio-resistant, but the risk benefit can be improved if you can increase the local dose effect without increasing the toxicity—which is a major issue in head and neck because we have 70 percent grade 3 or 4 toxicities (like mucositis) during the treatment and this sometimes prevents us from going up to the end of the treatment,” she concluded. Peter M. Goodwin is a contributing writer." @default.
• W2950280971 created "2019-06-27" @default.
• W2950280971 creator A5054494094 @default.
• W2950280971 date "2019-06-20" @default.
• W2950280971 modified "2023-10-18" @default.
• W2950280971 title "Hafnium Nanoparticles & Sarcoma Response to Radiotherapy" @default.
• W2950280971 doi "https://doi.org/10.1097/01.cot.0000569300.50577.07" @default.
• W2950280971 hasPublicationYear "2019" @default.
• W2950280971 type Work @default.
• W2950280971 sameAs 2950280971 @default.
• W2950280971 citedByCount "0" @default.
• W2950280971 crossrefType "journal-article" @default.
• W2950280971 hasAuthorship W2950280971A5054494094 @default.
• W2950280971 hasBestOaLocation W29502809711 @default.
• W2950280971 hasConcept C121608353 @default.
• W2950280971 hasConcept C126322002 @default.
• W2950280971 hasConcept C142724271 @default.
• W2950280971 hasConcept C143998085 @default.
• W2950280971 hasConcept C155672457 @default.
• W2950280971 hasConcept C171250308 @default.
• W2950280971 hasConcept C179104552 @default.
• W2950280971 hasConcept C185592680 @default.
• W2950280971 hasConcept C192562407 @default.
• W2950280971 hasConcept C2778256501 @default.
• W2950280971 hasConcept C502942594 @default.
• W2950280971 hasConcept C509974204 @default.
• W2950280971 hasConcept C534791751 @default.
• W2950280971 hasConcept C546638069 @default.
• W2950280971 hasConcept C71924100 @default.
• W2950280971 hasConceptScore W2950280971C121608353 @default.
• W2950280971 hasConceptScore W2950280971C126322002 @default.
• W2950280971 hasConceptScore W2950280971C142724271 @default.
• W2950280971 hasConceptScore W2950280971C143998085 @default.
• W2950280971 hasConceptScore W2950280971C155672457 @default.
• W2950280971 hasConceptScore W2950280971C171250308 @default.
• W2950280971 hasConceptScore W2950280971C179104552 @default.
• W2950280971 hasConceptScore W2950280971C185592680 @default.
• W2950280971 hasConceptScore W2950280971C192562407 @default.
• W2950280971 hasConceptScore W2950280971C2778256501 @default.
• W2950280971 hasConceptScore W2950280971C502942594 @default.
• W2950280971 hasConceptScore W2950280971C509974204 @default.
• W2950280971 hasConceptScore W2950280971C534791751 @default.
• W2950280971 hasConceptScore W2950280971C546638069 @default.
• W2950280971 hasConceptScore W2950280971C71924100 @default.
• W2950280971 hasIssue "12" @default.
• W2950280971 hasLocation W29502809711 @default.
• W2950280971 hasLocation W29502809712 @default.
• W2950280971 hasOpenAccess W2950280971 @default.
• W2950280971 hasPrimaryLocation W29502809711 @default.
• W2950280971 hasRelatedWork W2051549130 @default.
• W2950280971 hasRelatedWork W2120392252 @default.
• W2950280971 hasRelatedWork W2138425774 @default.
• W2950280971 hasRelatedWork W2152163150 @default.
• W2950280971 hasRelatedWork W2381389641 @default.
• W2950280971 hasRelatedWork W2384708512 @default.
• W2950280971 hasRelatedWork W2416044440 @default.
• W2950280971 hasRelatedWork W2797341450 @default.
• W2950280971 hasRelatedWork W2810299255 @default.
• W2950280971 hasRelatedWork W3111975802 @default.
• W2950280971 hasVolume "41" @default.
• W2950280971 isParatext "false" @default.
• W2950280971 isRetracted "false" @default.
• W2950280971 magId "2950280971" @default.
• W2950280971 workType "article" @default.